Intellia Therapeutics 미래 성장

Future 기준 확인 3/6

Intellia Therapeutics (는) 각각 연간 26.8% 및 66.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 33.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 68.7% 로 예상됩니다.

주요 정보

26.8%

수익 성장률

33.4%

EPS 성장률

Biotechs 수익 성장	41.8%
매출 성장률	66.8%
향후 자기자본 수익률	68.7%
애널리스트 커버리지	Good
마지막 업데이트	12 Dec 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:38I - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	78	-616	-483	-482	18
12/31/2025	53	-567	-439	-432	28
12/31/2024	53	-529	-400	-365	28
9/30/2024	43	-522	-363	-357	N/A
6/30/2024	46	-509	-383	-373	N/A
3/31/2024	53	-486	-418	-405	N/A
12/31/2023	36	-481	-408	-394	N/A
9/30/2023	52	-462	-407	-391	N/A
6/30/2023	53	-453	-384	-368	N/A
3/31/2023	53	-430	-379	-363	N/A
12/31/2022	52	-474	-392	-333	N/A
9/30/2022	51	-442	-355	-298	N/A
6/30/2022	45	-400	-342	-285	N/A
3/31/2022	38	-369	-309	-252	N/A
12/31/2021	33	-268	-238	-225	N/A
9/30/2021	27	-229	-221	-211	N/A
6/30/2021	42	-185	-181	-174	N/A
3/31/2021	52	-149	-69	-64	N/A
12/31/2020	58	-134	-53	-50	N/A
9/30/2020	62	-120	-43	-38	N/A
6/30/2020	51	-116	-41	-35	N/A
3/31/2020	46	-109	-126	-120	N/A
12/31/2019	43	-100	-110	-103	N/A
9/30/2019	40	-90	-89	-83	N/A
6/30/2019	37	-89	-76	-70	N/A
3/31/2019	33	-86	-71	-65	N/A
12/31/2018	30	-85	-68	-61	N/A
9/30/2018	29	-90	-81	-74	N/A
6/30/2018	29	-83	N/A	-78	N/A
3/31/2018	27	-76	N/A	-72	N/A
12/31/2017	26	-68	N/A	-65	N/A
9/30/2017	25	-54	N/A	-58	N/A
6/30/2017	23	-46	N/A	-49	N/A
3/31/2017	21	-38	N/A	34	N/A
12/31/2016	16	-32	N/A	36	N/A
9/30/2016	13	-26	N/A	45	N/A
6/30/2016	9	-22	N/A	49	N/A
3/31/2016	7	-18	N/A	-16	N/A
12/31/2015	6	-12	N/A	-2	N/A
9/30/2015	4	-14	N/A	1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 38I 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: 38I 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: 38I 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: 38I 의 수익(연간 66.8% ) German 시장( 5.7% 보다 빠르게 성장할 것으로 예상됩니다. 5.7% 연간).

고성장 수익: 38I 의 수익(연간 66.8% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 38I 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 68.7 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 16:02
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Intellia Therapeutics, Inc. 44 애널리스트 중 28 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Brian Skorney	Baird
Jack Allen	Baird
Huidong Wang	Barclays

Intellia Therapeutics 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Intellia Therapeutics, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics, Inc. Announces First Clinical Evidence from Ongoing Phase 1 Study That Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.38 loss in 3Q 2023)

Intellia Therapeutics, Inc. Presents Positive Results from the Phase 2 Study of NTLA-2002

Intellia Therapeutics, Inc. Announces Initiation of Haelo Phase 3 Study of Ntla-2002

Second quarter 2024 earnings released: US$1.52 loss per share (vs US$1.40 loss in 2Q 2023)

Intellia Therapeutics, Inc. Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Blueallele Corporation Files Lawsuit for Patent Infringement Against Intellia Therapeutics, Inc., for the Unauthorized Use of Blueallele’S Patented Bi-Directional Insertion Templates

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002

First quarter 2024 earnings released: US$1.13 loss per share (vs US$1.18 loss in 1Q 2023)

Intellia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

New minor risk - Shareholder dilution

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold €519k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold €234k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Second quarter 2021 earnings released: US$1.01 loss per share (vs US$0.61 loss in 2Q 2020)

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Index

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.63 loss in 1Q 2020)

Intellia Therapeutics, Inc. Announces the Presentation of New Data from Its CRISPR/Cas9 Platform

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

New 90-day low: €37.50

Full year 2020 earnings released: US$2.40 loss per share (vs US$2.11 loss in FY 2019)

Revenue misses expectations

New 90-day high: €60.00

Intellia Therapeutics, Inc. Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

New 90-day high: €41.59

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 in Vivo Sickle Cell Disease Treatments

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Revenue beats expectations

Third quarter 2020 earnings released: US$0.47 loss per share

New 90-day high: €22.96